Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL11087552 | 0.97 | LMNA (0.38) | LMNATSHRKCNA3MEN1KMT2A | |
| SCHEMBL4441268 | 0.85 | SLC6A2 (0.43) | LMNATSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL24525763 | 0.82 | MEN1 (0.42) | LMNATSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL8112308 | 0.82 | SLC6A2 (0.44) | LMNATSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL3518650 | 0.80 | SLC6A2 (0.51) | LMNATSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL3786109 | 0.77 | SLC6A2 (0.38) | LMNATSHRMEN1KMT2AHSD17B10 | |
| Hydrochloric Acid SCHEMBL8351844 | 0.76 | SLC6A2 (0.37) | LMNATSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL20887803 | 0.75 | OPRM1 (0.49) | LMNATSHRKCNA3MEN1KMT2A | |
| SCHEMBL13229259 | 0.75 | OPRM1 (0.51) | MEN1KMT2APRCPSIGMAR1OPRM1 | |
| SCHEMBL2987797 | 0.74 | SLC6A2 (0.37) | LMNATSHRMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289837-A1 | MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS | UNIV LJUBLJANI (SI) | 2025-09-18 | — | — | US | disclosed |
| EP-4511125-A1 | MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL K1.3 INHIBITORS | Univerza V Ljubljani (SI) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023203185-A1 | MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL K V1.3 INHIBITORS | UNIVERZA V LJUBLJANI (SI) | 2023-10-26 | — | — | WO | disclosed |
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| EP-2041142-B1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8399503-B2 | Spirocyclic azaindole derivatives | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090156593-A1 | Spirocyclic Azaindole Derivatives | GRUNENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2041142-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008009416-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0035902-B1 | 1-(4-ARYL-CYCLOHEXYL)PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-31 | — | — | EP | disclosed |
| US-4460604-A | ANALGESICS, NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1984-07-17 | — | — | US | disclosed |
| US-4329353-A | ANTIEMETIC AND NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-05-11 | — | — | US | disclosed |
| EP-0035902-A1 | 1-(4-Aryl-cyclohexyl)piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-09-16 | — | — | EP | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289837-A1 | MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS | KCNJ2, KCNN3, KCNA3 | LMNA 1596/4885TSHR 3808/4885KCNA3 3/4885 |
| US-20090156593-A1 | Spirocyclic Azaindole Derivatives | AZI2, TPMT, AADAC | LMNA 2504/4885TSHR 2673/4885KCNA3 3238/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | LMNA 1535/4885TSHR 2501/4885KCNA3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.